ProfileGDS5678 / 1425024_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 49% 48% 53% 49% 47% 49% 49% 48% 50% 49% 49% 47% 49% 49% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2158649
GSM967853U87-EV human glioblastoma xenograft - Control 23.1219848
GSM967854U87-EV human glioblastoma xenograft - Control 33.2887253
GSM967855U87-EV human glioblastoma xenograft - Control 43.1091849
GSM967856U87-EV human glioblastoma xenograft - Control 53.0521847
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2630449
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2462349
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.139648
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1686650
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1505649
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1490149
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0731447
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1626249
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1521749